Comparative Pharmacology
Head-to-head clinical analysis: ONCOVIN versus VINBLASTINE SULFATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ONCOVIN versus VINBLASTINE SULFATE.
ONCOVIN vs VINBLASTINE SULFATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vincristine is a vinca alkaloid that binds to tubulin, inhibiting microtubule formation and disrupting mitotic spindle assembly, leading to metaphase arrest and cell death.
Vinca alkaloid that inhibits microtubule formation by binding to tubulin, thereby disrupting mitotic spindle assembly and preventing cell division during metaphase.
1.4 mg/m2 IV weekly, maximum single dose 2 mg
Adult: 3.7-18.5 mg/m2 IV weekly, typically 6-8 mg/m2; dose titrated based on leukocyte count.
None Documented
None Documented
Terminal elimination half-life: approximately 19-155 hours (mean ~85 hours) in adults. In elderly and hepatic impairment, half-life is prolonged. Highly variable due to extensive tissue binding and prolonged terminal phase.
Terminal elimination half-life is approximately 25 hours (range 20-30 hours). This prolonged half-life supports a weekly dosing schedule.
Primarily hepatobiliary (fecal) excretion: ~80% as unchanged drug and metabolites via bile into feces. Renal excretion: <10% unchanged in urine. Extensive metabolism in liver via CYP3A4.
Primarily hepatobiliary. Approximately 95% of the dose is excreted in feces via bile, with less than 5% excreted unchanged in urine. Renal excretion is a minor pathway.
Category C
Category D/X
Vinca Alkaloid
Vinca Alkaloid